10-K: Encision Inc. Reports Reduced Net Loss and Increased Gross Profit Amidst Strategic Growth Initiatives for Minimally Invasive Surgery Devices

Encision Inc., a medical device company specializing in patient safety technology for minimally invasive surgery, reported a significant reduction in net loss and an increase in gross profit for fiscal year 2025, driven by higher service revenue and improved product margins, despite a slight decrease in overall product revenue.

Summary

• Net loss for fiscal year 2025 decreased significantly to $220,198, a substantial improvement from the $691,783 net loss reported in fiscal year 2024.
• Gross profit increased by 12% to $3,511,286 in fiscal year 2025, up from $3,135,962 in fiscal year 2024, with the gross profit margin improving from 48% to 54% of net product revenue.
• Total revenue for fiscal year 2025 was $6,555,315, a slight decrease from $6,585,882 in fiscal year 2024, primarily due to a 3% decrease in net product revenue to $6,217,687.
• Net service revenue saw a substantial increase to $337,628 in fiscal year 2025, compared to $153,913 in fiscal year 2024, largely due to engineering services performed under an agreement with Vicarious Surgical Inc.
• Cash used in operations for fiscal year 2025 was $54,948, a shift from cash provided by operations of $144,389 in fiscal year 2024.
• Working capital decreased to $1,036,850 at March 31, 2025, from $1,357,937 at March 31, 2024, primarily due to the net loss and increased utilization of the Pathward line of credit.
• The company maintains an accumulated deficit of $22,765,245 as of March 31, 2025.
• Encision Inc. holds 21 unexpired United States patents related to its Active Electrode Monitoring (AEM) technology, with remaining patent lives ranging from one to twenty years.
• The company employed 22 full-time and 2 part-time individuals as of March 31, 2025.
• Material weaknesses in internal control over financial reporting were identified due to inadequate segregation of duties, as management is comprised of only two persons.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While the company showed significant improvement in reducing its net loss and increasing gross profit, it still operates at a loss and used cash in operations. There are strong positives related to its patented technology and market endorsements, but also persistent challenges with liquidity, market penetration, and internal control weaknesses.

Positives

• Net loss significantly decreased to $220,198 in FY25 from $691,783 in FY24, indicating improved financial performance.
• Gross profit increased by 12% to $3,511,286 in FY25, with the gross profit margin improving from 48% to 54% of net product revenue, primarily due to a reduction in material costs on high-volume products and an increase in high-margin service revenue.
• Service revenue more than doubled to $337,628 in FY25, reflecting successful collaboration on the integration of AEM technology into Vicarious Surgical Inc.'s robotic surgical system.
• Proprietary and patented Active Electrode Monitoring (AEM) technology addresses a well-documented risk of unintended electrosurgical burn injury in minimally invasive surgery, enhancing patient safety.
• AEM technology has received endorsements from various groups, including surgeons, nurses, medicolegal community, malpractice insurance carriers, and electrosurgical device manufacturers.
• The U.S. Food and Drug Administration (FDA) issued a Safety Communication in May 2020, highlighting the risks of monopolar energy use and implicitly supporting the need for solutions like AEM technology.
• Secured contracts with the U.S. Department of Veterans Affairs (VA) and a Vizient Innovative Technology Contract in FY2020, providing access to large healthcare systems.
• Introduction of new products like the AEM EndoShield 2 Burn Protection System and AEM 2X enTouch Scissors aims to reduce reprocessing needs, lower cost per use, and expand market segments.
• General and administrative expenses decreased by 8% to $1,400,611 in FY25 due to reduced regulatory fees, compensation, and outside service expenses.
• Research and development expenses decreased by 5% to $593,152 in FY25, while still planning for product line expansion in FY26.

Negatives

• The company continues to operate at a net loss of $220,198 in fiscal year 2025, contributing to an accumulated deficit of $22,765,245.
• Cash used in operations was $54,948 in fiscal year 2025, a reversal from cash provided by operations of $144,389 in fiscal year 2024, indicating a negative operational cash flow.
• Net product revenue decreased by 3% to $6,217,687 in fiscal year 2025, primarily due to a decrease in non-essential surgical procedures.
• Working capital decreased to $1,036,850 at March 31, 2025, from $1,357,937 at March 31, 2024, indicating a weakening liquidity position.
• Identified material weaknesses in internal control over financial reporting due to inadequate segregation of duties, as management is comprised of only two persons (Principal Executive Officer and Principal Financial Officer/Principal Accounting Officer).
• The common stock is thinly traded, and its prices are volatile, with the actions of a few shareholders potentially adversely affecting the stock price.
• The company depends on single-source suppliers for certain key components, posing a risk of manufacturing interruption if supply is limited or lost.
• The Certificate of Export from the United States Department of Health and Human Services has expired, which may hinder international sales efforts until renewed.
• The company has incurred losses of approximately $23 million since its inception in 1991 and may need additional funding to support operations.
• The competitive landscape is dominated by large, well-financed companies with significantly greater resources and market recognition.

Risks

• Products may not be accepted by the market in commercially viable quantities, requiring continuous education on the hazards of conventional electrosurgical products.
• Difficulty in continually developing and training the network of direct and independent sales representatives and expanding international distribution efforts, which may take longer than expected and incur retraining costs.
• Inherent flaws and inefficiencies in the independent sales representative network, including conflicts of interest and competing products.
• Need for additional funding to support operations, with no assurance of raising capital on acceptable terms or at all, potentially leading to dilution of existing stockholders or restrictive debt covenants.
• Inability to compete successfully against current manufacturers of conventional electrosurgical instruments or alternative surgical technologies (bipolar electrosurgery, harmonic scalpel, lasers), which have greater financial, technical, and marketing resources.
• Failure to continually enhance products and keep pace with rapid technological changes, leading to product obsolescence or inability to attract and retain customers.
• Changes in government regulations or failure to comply with existing/new regulations could lead to missed market opportunities, increased costs, and limited growth.
• Tariffs may increase material costs, negatively affecting gross profit margins if fully absorbed.
• Failure to comply with extensive regulatory requirements governing manufacturing could result in fines, suspensions, product recalls, or criminal prosecution.
• Current patents, trade secrets, and know-how may not provide a competitive advantage, pending applications may not result in patents, and competitors may design around existing patents.
• Dependence on single-source suppliers for key components and subcontractors for materials, leading to potential manufacturing interruptions or limitations on growth strategy.
• Potential fluctuation in future quarterly results due to market acceptance, investments, competition, and economic conditions, causing stock price volatility.
• Product liability claims may exceed current insurance coverage, leading to material adverse effects on financial position.
• Dependence on certain key personnel, particularly the President and CEO, Gregory J. Trudel, with the loss of key personnel potentially having a material adverse effect.
• Cybersecurity-related attacks, significant data breaches, or disruption of information technology systems could negatively affect the business, leading to unauthorized access, data loss, regulatory actions, and reputational damage.
• Net operating loss carryforwards and research credits may expire if not utilized, and their use may be limited by certain events, including changes in ownership.

Future Outlook

The company's fiscal year 2026 operating plan is focused on growing revenue, increasing gross profits, increasing research and development costs, and ultimately increasing profits and positive cash flows. It expects to generate increased sales in the U.S. from new hospital customers and grow AEM instrumentation sales to existing accounts through a campaign focused on clinical, economic, and safety benefits, a medico-legal initiative, and new AEM products. New refinements to the AEM product lines are planned for introduction in fiscal year 2026. Management believes that cash resources and borrowing capacity will be sufficient to fund operations for at least the next twelve months under the current operating plan.

Management Comments

• Management believes that AEM technology is following a similar path as previous technological developments in surgery, such as isolated electrosurgical generators and REM technology, in becoming a standard of care.
• Management believes that improvement in the quality of sales representatives carrying the AEM product line, along with increased marketing efforts and the introduction of new products, may provide the basis for increased sales and continuing profitable operations.
• Management expects to generate increased sales in the U.S. from sales to new hospital customers and to grow AEM instrumentation sales to existing accounts in fiscal year 2026.
• Management believes that if fiscal year 2026 revenues increase, then fiscal year 2026 gross profit and gross margin, as a percentage of revenue, will increase due to a higher gross margin on product produced.
• Management believes that sales and marketing expenses will need to be maintained at a healthy level to expand market visibility and optimize field sales capability.
• Management believes that producing products internally will allow for cost reductions and better control over quality and consistency.
• Management concludes that it is probable that cash resources and the line of credit will be sufficient to meet cash requirements for twelve months from the issuance of the financial statements.

Industry Context

The medical device industry is experiencing an increase in minimally invasive surgery (MIS), which offers patient benefits but also introduces new risks, particularly from stray electrosurgical energy. The market for laparoscopic monopolar electrosurgical instruments, which Encision targets, is estimated at $500 million annually in the U.S. and is growing. The industry is highly competitive, dominated by large, well-financed companies like Medtronic plc (Advanced Surgical Technologies Group) and Johnson & Johnson (Ethicon Endo-Surgery). There's a growing public and regulatory interest in reducing medical errors and advancing patient safety, as evidenced by FDA Safety Communications and CMS Hospital Quality Metrics, which aligns with Encision's AEM technology that aims to eliminate stray electrosurgical burns.

Comparison to Industry Standards

• The document does not provide specific comparable financial metrics or project results from competitors (e.g., Medtronic plc, Johnson & Johnson, Olympus Corporation, Lumenis) to allow for a detailed assessment against global industry benchmarks. It primarily focuses on the unique patient safety benefits of AEM technology as a differentiator against conventional instruments and alternative energy technologies.
• While the document asserts that AEM technology 'completely eliminates' the risk of stray energy burns, unlike competitive technologies that 'somewhat reduce' it, it does not quantify the market share or adoption rates of these competing solutions for a direct comparative analysis of market penetration or clinical outcomes across specific projects or hospitals.

Corporate Governance

Legal Proceedings

• The company is involved in various disputes, claims, suits, investigations, and legal proceedings arising in the ordinary course of business.
• Management believes that the resolution of current pending legal matters will not have a material adverse effect on the business, financial condition, results of operations, or cash flows.

Related Party Transactions

• The company engaged Finance Vision Service, Inc., a company owned by board member Robert Fries, for consulting services.
• Payments to Finance Vision Service, Inc. totaled $40,727 in fiscal year 2025 and $32,032 in fiscal year 2024.

Stakeholder Impact

• **Shareholders**: Face potential dilution if additional funds are raised through equity issuance. The thinly traded nature of the common stock and its volatility mean actions of a few shareholders can significantly affect price. The accumulated deficit and continued net loss impact shareholder equity.
• **Employees**: Relations are considered good, and none are covered by a collective bargaining agreement. The company offers a 401(k) Profit Sharing Plan. However, the small management team (two persons) creates internal control weaknesses, potentially increasing workload or risk for existing staff.
• **Customers (Hospitals/Surgeons)**: Benefit from enhanced patient safety through AEM technology, which aims to prevent stray electrosurgical burns. The introduction of new products like EndoShield 2 and 2X Scissors offers cost-effectiveness and ease of adoption. The company's efforts to expand its sales network aim to increase access to its products.
• **Suppliers**: The company's dependence on single-source suppliers for certain key components creates a risk of supply interruption, which could impact manufacturing and product availability.
• **Creditors**: The company has a line of credit and secured notes, and its ability to sustain profitability and positive cash flows is crucial for meeting debt obligations. The decrease in working capital and cash used in operations in FY25 could be a concern for creditors.

Next Steps

• Focus on growing the AEM franchise in fiscal year 2026 through a campaign highlighting clinical, economic, and safety benefits.
• Implement a medico-legal initiative to further advance AEM technology adoption.
• Introduce new AEM products and refinements to the existing product line in fiscal year 2026.
• Continue efforts to expand domestic and international distribution capabilities.
• Explore options for additional financing, including securing a larger credit facility, sales of debt or equity securities, licensing technology, and strategic alliances.
• Monitor and reassess the effectiveness of internal controls, including the feasibility of hiring additional staff for better segregation of duties and expanding the board with independent members.

Key Dates

Recommendation

Keywords

Medical Devices, Minimally Invasive Surgery, Electrosurgery, Patient Safety, Active Electrode Monitoring, AEM Technology, Laparoscopic Instruments, Surgical Instruments, FDA, Patents, Healthcare, Financial Performance, SEC Filing, 10-K, Corporate Governance, Risk Management